Skip to main content
Clinical Trials/NL-OMON24029
NL-OMON24029
Not yet recruiting
Not Applicable

The identification and validation of risk factors to enable objective risk-stratification to predict malignant progression in Barrett’s Esophagus: a prospective multi-center study in community hospitals in the Amsterdam region

Department of Gastroenteroogy and Hepatology, Amsterdam University Medical Centres (Amsterdam UMC)0 sites700 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of Gastroenteroogy and Hepatology, Amsterdam University Medical Centres (Amsterdam UMC)
Enrollment
700
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Department of Gastroenteroogy and Hepatology, Amsterdam University Medical Centres (Amsterdam UMC)

Eligibility Criteria

Inclusion Criteria

  • Aged between 18 and 75 years
  • \-Endoscopic and histological evidence of NDBE (defined as intestinal metaplasia without dysplasia) with a circumferential extent of \=2 cm and a total maximum extent of \=10 cm
  • \-Ability to provide a written informed consent

Exclusion Criteria

  • \-Visible lesions in the esophagus suspicious for neoplasia during the first endoscopy (according to the Paris classification)
  • \-History of HGD or EAC in the esophagus
  • \-Unfit for endoscopic surveillance or inability to obtain biopsies
  • \-History of endoscopic or surgical treatment for esophageal dysplasia or EAC
  • \-History of esophageal surgery other than fundoplication
  • \-Presence of grade C or grade D erosive esophagitis (according to Los Angeles classification)
  • \-Refusal or inability to provide written informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials